

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization**  
International Bureau



**(43) International Publication Date**  
**12 December 2002 (12.12.2002)**

**PCT**

**(10) International Publication Number**  
**WO 02/099129 A2**

**(51) International Patent Classification<sup>7</sup>:**

**C12Q 1/68**

**(74) Agent:** CAMPBELL, Patrick, John, Henry; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

**(21) International Application Number:** PCT/GB02/02640

**(22) International Filing Date:** 7 June 2002 (07.06.2002)

**(81) Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

**(25) Filing Language:**

English

**(26) Publication Language:**

English

**(30) Priority Data:**

0113908.8

7 June 2001 (07.06.2001) GB

**(71) Applicant (for all designated States except US):** UNIVERSITY COLLEGE LONDON [GB/GB]; Gower Street, London WC1E 9BT (GB).

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**(72) Inventors; and**

**(75) Inventors/Applicants (for US only):** GRIFFITHS, David, John [GB/GB]; Wohl Virion Centre, Windeyer Institute of Medical Sciences, University College London, 46 Cleveland Street, London W1T 4JF (GB). KELLAM, Paul [GB/GB]; Wohl Virion Centre, Windeyer Institute of Medical Sciences, University College London, 46 Cleveland Street, London W1T 4JF (GB). WEISS, Robert, Anthony [GB/GB]; Wohl Virion Centre, Windeyer Institute of Medical Sciences, University College London, 46 Cleveland Street, London W1T 4JF (GB).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 02/099129 A2**

**(54) Title:** DESIGNING DEGENERATE PCR PRIMERS

**(57) Abstract:** A method of designing PCR primers for screening for new members of known virus families.

## DESIGNING DEGENERATE PCR PRIMERS

### Field of the invention

The invention relates to a method of designing a panel of primers for detecting viruses in a high throughput polymerase chain reaction assay.

### Background of the invention

5 All organisms appear to be capable of infection by viruses, including bacteria, animals and plants. Viruses require the use of the cellular translation and transcription machinery to replicate. In the process of replication they often have deleterious effects on the host cell and thus on the host organism. Viruses constitute an important class of pathogens causing many diseases, leading to loss of life in  
10 humans and economic loss in the agricultural industries.

### Summary of the invention

The polymerase chain reaction (PCR) allows the amplification of a specific region of a polynucleotide. The specificity of the reaction is due to the primers  
15 which during the course of PCR bind to the region to be amplified in a sequence specific manner. The invention provides a method of designing primers which can be used in high throughput screening to detect viruses. The method may be used to detect unknown viruses which have not yet been sequenced.

In particular the invention provides a method of designing a panel of  
20 degenerate primer pairs for screening for new members of multiple known virus families in a biological sample, wherein each primer pair in the panel binds a sequence that is conserved across members of a said virus family and selectively directs amplification of sequence of said family by PCR, which method comprises  
(a) providing a plurality of amino acid sequences from members of a first  
25 virus family,  
(b) comparing the sequences to identify conserved regions,  
(c) designing a first primer pair using a computer based method, wherein each primer in the pair binds a nucleotide sequence that encodes a conserved region

-2-

identified in (b) and wherein the primer pair is designed to amplify by PCR the nucleotide sequence between the nucleotide sequences that encode conserved regions in members of the first virus family, and

(d) repeating steps (a) to (c) for each virus family.

5 The invention also provides a method of designing a panel of degenerate primer pairs for screening for new members of multiple known virus families in a biological sample, wherein each primer pair in the panel binds a sequence that is conserved across members of a said virus family and selectively directs amplification of sequence of said family by PCR, which method comprises

10 (a) providing a plurality of nucleotide sequences from members of a first virus family,

(b) comparing the sequences to identify conserved regions,

15 (c) designing a first primer pair using a computer based method, wherein each primer in the pair binds a conserved region identified in (b) and wherein the primer pair is designed to amplify by PCR the nucleotide sequence between the conserved regions in members of the first virus family, and

(d) repeating steps (a) to (c) for each virus family.

The invention additionally provides a panel of primers which has been designed by the method of the invention.

20

#### Detailed description of the invention

The invention provides a method of designing a panel of primer pairs which can be used in high throughput virus screening. The method comprises initial steps which deduce the sequences of the primers using computer based calculations, and 25 optional later steps in which the primers are synthesised and tested empirically, for example to determine optimal PCR conditions and/or to select primer pairs with desired further properties.

The panel of primers provided by the method are designed to be capable of detecting unknown viruses based on nucleotide and/or amino acid sequences in the 30 unknown virus which are similar (homologous) to nucleotide and/or amino acid sequences in a known virus. These conserved sequences typically have a role in

providing a necessary or advantageous activity or property to the virus. Conserved nucleotide sequences may be coding or non-coding sequences.

In one embodiment the conserved sequences code for or are from virus proteins which have the following activities: DNA or RNA polymerase (replicase), 5 topoisomerase (helicase/gyrase), endonuclease (integrase), nucleic acid binding protein, protease, transcription factors, envelope glycoproteins, structural protein (e.g. capsid or nucleocapsid protein).

The panel of primers is designed to detect viruses which are single stranded or double stranded DNA or single stranded or double stranded RNA viruses. The 10 viruses are generally capable of infecting prokaryotic or eukaryotic cells, such as bacterial, animal, plant, yeast or fungal cells. Preferably the viruses are mammalian (preferably primate) or avian viruses, such as human, pig, horse, sheep, goat, cow, chicken, turkey or duck viruses.

The viruses are typically from any combination of the following families: 15 Adenoviridae, Arenaviridae, Arteriviridae, Astroviridae, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Deltavirus, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Papovaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Polydnnaviridae, Poxviridae, Reoviridae, Retroviridae, Rhabdoviridae, Togaviridae or Bornavirus.

20 The primers of the panel are capable of detecting unknown viruses in a biological sample. Such a sample either originates from a single individual or is a pooled sample from individuals of the same species. Thus the panel of primers detects viruses which infect the same species (from which the sample originates).

Generally in the method at least 15, 30, 50, 100, 200 or more, typically up to 25 a maximum of 300 different primer pairs are designed. The primer pairs designed in the method bind sequence which is conserved across members of a virus family. The panel which is designed in the method may comprise primer pairs that bind sequence which is conserved across substantially all members of the family or across a subset of the members of the family, for example across all members of a subfamily or of a 30 genus. Generally, the primer pairs bind at least 70%, at least 80%, or at least 90% of the known viruses of the family, subfamily or genus. Preferably less than 10, such as

less than 5, primer pairs will be used for the detection of any given family, subfamily or genus in the panel.

The panel of primer pairs is generally capable of detecting viruses from at least 10, 15, 20, 30 or more families, typically up to a maximum of 35 families.

5 The panel of primer pairs may comprise sets of primer pairs which perform a nested PCR reaction. Generally such a set of primer pairs comprises a first and second primer pair. The first primer pair is able to amplify a template nucleotide sequence from a virus to form a PCR product. The second primer pair is able to amplify a nucleotide sequence using the PCR product generated by the first primer 10 pair as a template. The use of nested sets of primer pairs allows increased sensitivity.

In a preferred embodiment each primer pair is specific for a particular virus family, so that it does not detect viruses of other families.

15 In the method of the invention the plurality of amino acid sequences or nucleotide sequences are provided from different known viruses of the same family. The amino acid sequences or nucleotide sequences will be for the same protein of the different viruses. Typically at least 5, 10, 20, 50, 100 or more sequences are provided. The maximum number of sequences provided will, for example, be 300 sequences.

20 Each of the sequences which is provided is typically at least 20, 50, 100, 200 or more amino acids or nucleotides in length. In general the maximum length of the nucleotide sequences is 1000 nucleotides and the maximum length of the amino acid sequences is 300 amino acids. The sequences may be obtained from a database of sequences, such as GenBank. The sequences may be obtained from a database comprising virus sequences which are organised into homologous protein families 25 (based on sequence similarity relationships).

30 In a preferred embodiment the sequences are obtained from the VIDA database (described in Alba et al (2001) Nucleic Acids Research 29, 133-136) or the Virus Division of GenBank. The sequences may be provided in the form of a database, preferably in computer-readable form. The sequences are preferably provided in the form of a computer-readable database constructed using programs which identify homologous protein families, such as GeneTableMaker, MKDOM or

-5-

PSCBuilder.

The sequences which have been provided are compared to identify conserved regions. Typically such conserved regions will have a length of at least 12 nucleotides, such as at least 15, 21, 27, 36, 99 or more nucleotides (generally up to a 5 maximum length of 200 nucleotides) or at least 4, 5, 7, 10, 25 or more amino acids (generally up to a maximum length of 50 amino acids).

Across the conserved region the virus sequences which are being provided will of course share identity or similarity. Typically the amino acids or nucleotides in at least 50% of the positions in the region will be the same in at least 50 %, 60%, 10 70%, or 80% of the viruses of the group (i.e. in the family, genus or subfamily).

The algorithm which identifies conserved regions generally uses a multiple sequence alignment method. The method may comprise (a) aligning all pairs of sequences separately to calculate a distance matrix giving the divergence of each pair of sequences, (b) calculating a guide tree from the distance matrix, and (c) aligning 15 the sequences progressively according to the branching order in the guide tree.

A preferred algorithm for the aligning the conserved sequences is CLUSTALW as described in Thompson et al (1994) Nucleic Acids Research 22, 4673-80. Other algorithms that can be used for aligning sequences are MultAlin (Corpet (1988) Nucleic Acids Research 16, 10881-90) or Jalview (Clamp et al (1998) 20 <http://barton.ebi.co.uk>). BLOCKS of conserved regions of amino acids may be extracted from the multiple alignments, typically using the program Blocks Multiple Alignment Processor. Alternatively the entire process of performing multiple alignments and extracting BLOCKS can be performed using BLOCKMAKER (Henikoff and Henikoff (1994) Genomics 19, 97-107).

25 The output from the alignment and BLOCK extraction set (i.e. the information describing the identified conserved regions) is then entered into the algorithm which designs the primers. Such output is typically in the form of partial sequences which correspond to the conserved regions (BLOCKS). These BLOCKS are input into a primer design algorithm. In one embodiment such an algorithm is 30 CODEHOP.

In the primer design step the conserved regions which are chosen as targets

for primers preferably comprise few codons with degenerate counterparts, i.e. preferably the sequence has a low redundancy, such as a redundancy of less than 512 fold, 256 fold or 128 fold. Each primer binds in accordance with Watson-Crick base pairing and thus the binding is sequence specific. Each primer will thus be designed 5 to be wholly or partially complementary to the sequence to which it binds.

Each of the primers typically has a length of at least 8 nucleotides, such as at least 10, 12, 15, 20, 30, 40 or more nucleotides (up to a maximum of 50 nucleotides for example). In one embodiment the primer may comprises at least 2, 4 or 6, up to a maximum of 10 for example, inosine bases. Inosine is able to bind to any of the four 10 nucleotides and therefore use of inosine causes a reduction in effective redundancy.

Each primer pair will be designed so that the PCR product generally has a length of at least 20, such as at least 50, 100, 200, 500, 1000 or more nucleotides (and typically up to a maximum of  $5 \times 10^3$  nucleotides long).

Each primer is preferably designed so that it anneals to a single site, i.e. the 15 primer will not bind to any other site in the genome of the relevant virus.

Each primer is preferably designed so that it does not exhibit secondary structure, i.e. the nucleotides in the primer will not bind substantially to any other nucleotide in the primer apart from those to which it is covalently linked. In addition preferably each primer is designed so that it does not bind other primers with the 20 same sequence.

In one embodiment the 3' region, and preferably the 3' terminal nucleotide of the primer binds to the target sequence with high affinity, thus preferably this region or nucleotide comprises a G or C.

Generally each primer is designed to have an annealing temperature of from 25 30 to 65°C, such as 50 to 60°C or 35 to 45°C. In addition each primer pair may be designed to ensure that the two primers do not bind to each other.

The primers are designed by a computer based algorithm. In one embodiment such an algorithm designs primers according to the following rules:

1) A set of blocks is input, where a block is an aligned array of amino acid 30 sequence segments without gaps that represents a highly conserved region of homologous proteins. A weight is provided for each sequence segment, which can be

increased to favour the contribution of selected sequences in designing the primer. A codon usage table is chosen for the target genome.

2) An amino acid position-specific scoring matrix (PSSM) is computed for each block using the odds ratio method.

5 3) A consensus amino acid residue is selected for each position of the block as the highest scoring amino acid in the matrix.

4) For each position of the block, the most common codon corresponding to the amino acid chosen in step 3 is selected utilizing the user-selected codon usage table. This selection is used for the default 5' consensus clamp in step 8.

10 5) A DNA PSSM is calculated from the amino acid matrix (step 2) and the codon usage table. The DNA matrix has three positions for each position of the amino acid matrix. The score for each amino acid is divided among its codons in proportion to their relative weights from the codon usage table, and the scores for each of the four different nucleotides are combined in each DNA matrix position.

15 Nucleotide positions are treated independently when the scores are combined. As an option, the highest scoring nucleotide residue from each position can replace the most common codons from step 4 that are used in the consensus clamp.

20 6) The degeneracy is determined at each position of the DNA matrix based on the number of bases found there. As an option, a weight threshold can be specified such that bases that contribute less than a minimum weight are ignored in determining degeneracy.

25 7) Possible degenerate core regions are identified by scanning the DNA matrix in the 3' to 5' direction. A core region must start on an invariant 3' nucleotide position, have length of 11 or 12 positions ending on a codon boundary, and have a maximum degeneracy of 128 (this is the default setting of CODEHOP). The degeneracy of a region is the product of the number of possible bases in each position.

30 8) Candidate degenerate core regions are extended by addition of a 5' consensus clamp from step 4 or 5. The length of the clamp is controlled by a melting point temperature calculation (the CODEHOP default is 60°C) and is usually about 20 nucleotides.

-8-

9) Steps 7 and 8 are repeated on the reverse complement of the DNA matrix from step 5 for primers corresponding to the opposite DNA strand.

In one embodiment CODEHOP (Rose et al (1998) Nucleic Acids Research 26, 1628-1635) is used to design the primer pairs. This program uses the above 5 rules.

The primers designed by the algorithm may then be mapped back to the original sequence to choose primer pairs which provide the desired length of PCR product.

The above-described computer based method is repeated until the desired 10 number of primer pairs have been designed. Optionally the primer pairs can then be synthesised and tested. They are typically tested to determine the optimal conditions for using the primers in a PCR reaction.

The PCR reaction is carried out in a PCR mixture that generally comprises the following: the template polynucleotide (which will be amplified in the event of 15 virus detection), one or more primer pairs designed as described above, a polymerase enzyme (typically a DNA polymerase, such as Taq polymerase), deoxynucleotide triphosphates (dATP, dTTP, dCTP and dGTP) and a suitable buffer.

The PCR reaction generally comprises cycles of the following steps: a denaturation step, a primer annealing step and a polynucleotide synthesis step. 20 Typically the PCR reaction comprises at least 25 cycles, such as 30, 35, 40 or more cycles, up to a maximum of 60 cycles for example. Generally in the denaturation step the PCR mixture is heated to a temperature at which the polynucleotides in the PCR mixture (in particular the polynucleotide region to be amplified) denature to single stranded form. The denaturing temperature is generally from 85 to 98°C.

25 In the primer annealing step the primers bind to template nucleotide sequence in a sequence specific manner. This step is generally carried out at a temperature of from 30 to 65°C. In the polynucleotide synthesis step the polymerase replicates/synthesises nucleotide sequence based on template sequence by addition of nucleotides to the 3' end of the bound primers. This step is generally carried out at 30 about 72°C.

In one embodiment the primers are tested for their ability to amplify one or

more of the plurality of nucleotide sequences from known viruses which were used to design the primers, or in the case of amino acid sequences from known viruses being used to design the primers the primers may be tested for their ability to amplify the nucleotide sequence from the virus which encodes the amino acid sequence.

5        The primers may be tested in a range of buffer conditions to determine optimal buffer conditions for PCR using the primers. The buffer conditions which may be tested include pH (typically between 7 and 10), magnesium concentration (typically from 0.5 mM to 5 mM), potassium chloride (typically from 0 to 100 mM), ammonium chloride (typically 0 to 100 mM), glycerol (typically 0 to 20%),  
10      dimethylsulphoxide (typically 0 to 20%), ethanol (typically 0 to 20%), sorbitol (typically 0 to 20%) or betaine (typically 1M betaine).

The primers may be tested at a range of different temperatures to determine the optimal temperatures in the PCR reaction. Preferably the primers are tested in PCR reaction in which a range of primer annealing temperatures are tested.

15      Typically the range of temperatures is from 30 to 65 °C.

The panel of primer pairs or a group of primers within the panel may be designed to be used together on the same plate (i.e. using the same thermal cycles). Thus such primer pairs will be designed to work at the same annealing temperature.

20      In one embodiment a group of primer pairs within the panel are designed to have similar optimal conditions for use in PCR so that they can be used optimally in the same well or reaction vessel, i.e. that they can be used in multiplex PCR. Such a group typically comprises at least 2, 3, 4, 5, 6 or more primer pairs (up to a maximum of 8 primer pairs for example).

25      To provide such primer pairs the computer based method steps may be used to design primer pairs which are calculated to have similar annealing temperatures and/or the primers are tested to select primer pairs which can be used optimally together. Such testing typically determines whether the primers work optimally with the same buffers and/or whether the primers have similar annealing temperatures.

30      In one embodiment at least one or both primers of each primer pair in the group carries a label. Typically at least one of the primers in each primer pair will carry a different label from that used for the other primer pairs. The PCR product

-10-

generated by labelled primers carries the labels present on the primers. Thus after the group of primers have been used for PCR in the same well detection of the labels in the PCR products can be used to deduce which PCR product was formed from each primer pair. In one embodiment all forward primers of the group are labelled with 5 one colour and the reverse primers are labelled with a different colour.

In a preferred embodiment the primers are labelled with a fluorescent label, such as fluorescein based labels (e.g. fluorescein isothiocyanate). Different primer pairs may be labelled with fluorescent labels of different colours. The fluorescent labels which are used may be capable of detection by a Beckman CEQ2000<sup>TM</sup> or 10 Applied Biosystems A3700<sup>TM</sup> fluorescent DNA analyser. The fluorescent labels may be obtained from Beckman Coulter or Applied Biosystems.

Another way of being able to determine which PCR products are generated by which primer pair is for each primer pair in the group to generate a PCR product of different size to the PCR products generated by the other primer pairs of the 15 group. Typically each PCR product which is generated by the group of primers differs in size from all the other PCR products by at least 20, such as at least 50, 100, 200, 500, 1000 or more nucleotides. Each PCR product may for example differ in size from all other PCR products by up to a maximum of 3000 nucleotides.

The following Example illustrates the invention:

20 Example

The Example below refers to Figure 1 which shows how primers were designed using a database known as 'VIDA', and computer programs known as 'CLUSTALW', 'BLOCKMAKER' (or 'BLOCKS') and 'CODEHOP'.

25 Designing a panel of primers

A panel of primers was designed for detecting unknown viruses from the family Herpesviridae according to the strategy shown in Figure 1. The amino acid sequences of herpes virus DNA packaging protein UL15 were obtained from the VIDA database (Alba et al, see above). These sequences are shown in Table 1.

30 The sequences obtained from the VIDA database were then imported into CLUSTALW. This compares the protein sequences to identify conserved regions

-11-

and then aligns the sequences according to the conserved regions. The alignment produced by CLUSTALW is shown in Table 2.

The BLOCKMAKER program was then used to extract blocks of conserved aligned sequences which do not contain gaps from CLUSTALW and enter them into 5 CODEHOP. The primer sequences were then designed by CODEHOP using the conserved sequences. The output from the CODEHOP program is shown in Table 3. The 'Complement of Block' sequences shown in Table 3 shows the sequence of the other strand allowing primers to be designed for amplification in the opposite direction.

-12-

Table 1. All protein sequences of DNA packaging protein UL15 extracted from VIDA.  
Here written as a list and unaligned.

>gi\_10180719

5 MFGGLLGEETKRHFERLMKTKNDRLGASHRNER SIRDGDMVDAPFLNFAIPVPRRHQTVMPAIGILHNCC  
DSLG IYSAITTRMLYSSIA CSEFDELRRDSVPRCYPRITNAQAFLS PMMMRVANS II FQEYDEMECAAH R  
NAYYSTMNSFISMRTSDAFKQLTVFISRFSKLLIASFRDVNKLDHDHVKRARI DAPS YDKLHGTLELFQ  
KMI LMHATYFVTSVLLGDAERAERLLRVA FDTPHFS DIVTRHFRQRATVFLVPRRHGK TWFLVPLI ALA  
MSSFEGIRIGYTSHIRKAIEPV FEDIGDRLRRWFGAHRV DHVKG ETITFSF PSLKSTVTFASSHNTNS I

10 RGQDFNLLFVDEANFIRPDAVQTI I GFLNQATCKI I FVSS TNSGKASTSFLYGLKGSADDLLNVVTTY ICD  
EHMKHVTDYTNATSCSCYV LNKPVFITMDGAMRRTAEMFLPDSFMQ EIIIGGGVV DRTICQGDRSIFTASA  
IDRFLIYRPSTVNNQDPFSQDLYVYVDP AFTANTKASGTGVAVIGKYGTDYIVFGL EHYFLRALTGESSD  
SIGYCV AQC LIQ ICAI HRKRGV KIAIEGNSNQD SAVAIATRIAIE MISMKA AVAPTPHNVSFYHSKS  
NGTDVEYPYFLLQRQKTTAF DFFIAQFNSGRVLASQDLVSTTVSLT TD PVEYLTKQLTN ISEVVTGPTCT

15 RTFSGKKGGNDDTVVALTM A VY I SAH I PDM AFAPIRV

>gi\_7673189

MFGGLLGEETKRHFERLMKTKNDRLGASHRNER SIRDGDMVDAPFLNFAIPVPRRHQTVMPAIGILHNCC  
DSLG IYSAITTRMLYSSIA CSEFDELRRDSVPRCYPRITNAQAFLS PMMMRVANS II FQEYDEMECAAH R  
NAYYSTMNSFISMRTSDAFKQLTVFISRFSKLLIASFRDVNKLDHDHVKRARI DAPS YDKLHGTLELFQ  
20 KMI F DACHLFCNCFTWRSRRASERLLRVA FDTPHFS DIVTRHFRQRATVFLVPRRHGK TWFLVPLI ALA  
MSSFEGIRIGYI SHIRKAIEPV FEDIGDRLRRWFGAHRV DHVKG ETITFSF PSLKSTVTFASSHNTNS I  
RGQDFNLLFVDEANFIRPDAVQTI I GFLNQATCKI I FVSS TNSGKASTSFLYGLKGSADDLLNVVTTY ICD  
EHMKHVTDYTNATSCSCYV LNKPVFITMDGAMRRTAEMFLPDSFMQ EIIIGGGVV DRTICQGDRSIFTASA  
IDRFLIYRPSTVNNQDPFSQDLYVYVDP AFTANTKASGTGVAVIGKYGTDYIVFGL EHYFLRALTGESSG

25 SIGYCV AQC LIQ ICAI HRKRGV KIAIEGNSNQD SAVAIATRIAIE MISMKA AVAPTPHNVSFYHSKS  
NGTDVEYPYFLLQRQKTTAF DFFIAQFNSGRVLASQDLVSTTVSLT TD PVEYLTKQLTN ISEVVTGPTCT  
RTFSGKKGGNDDTVVALTM A VY I SAH I PDM AFAPIRV

>gi\_5689285

MFGGALGESAKKHFERLLRDRNERLGASRKNECLARGGSLVDAPFLNFAISVPRRHQTVMPAVGTLHDCC

30 DGTG IYSAIATRLLYAGIVSSEFGEVRRESLSNGHISKRNREALLAPTLTRVANSITFHEYDDAQC AHR  
NAYYSTMNTFGSMRTSDAFQOLASFIDRFSKLLAASFKDVNILD RNNAPKRARI TAPS YDKPHG TLELFQ  
KMI LMHATYFLTSVLL DHAERAERLLRVI FDI PDFS DAA TRHFRQRATVFLVPRRHGK TWFLVPLI ALA  
MSSFEGIRIGYTSHIRKAIEPV FEEIGDRLRRWFGTQCV DHVKG ETITFSF PSLKSTVTFASSHNTNS I  
RGQDFNLLFVDEANFIRPDAVQTI I GFLNQANCKI I FVSS TNSGKASTSFLYGLKGSADDLLNVVTTY ICD

35 EHMKHVTNYTNATSCSCYV LNKPVFITMDGAMRRTAEMFLPDSFMK EIIIGG I TMDRNTCQGDRGVFTASA  
VERLLLYRPSTVRNQDILS RDLYVYVDP AFTANTRASGTGIAVIGRYGADYI I FGLEHFFL RALTGE SAD  
AIGECAAQCIAQ ICAI H CERFTIRVAEGNSNQD SAVAIATRISIDL ASYVQSGVAPAPHDVCFYHSKP  
AGSNVEYPFLLQRQKTA AF DFFIARFNSGRVLASQDLVSTTISLSTD PVEYLTKQLTN ISEVVTGATGT  
RTFSGKKGGYDDTVVALVM A VY I SAHAS DATF APIRGVEATCRGPTEA

40 >gi\_1869837

MFGQOLASDVQQYLERLEKQRQQKVG VDEASAGLTLGGDALRVPFLDFATATPKRHQT VVPGVGTLHDCC  
EHSPLFSAVARRLLFNSLVP AQLRGRDFGGDHTAKLEFLA PELVRAV LRFRECAPEDAVPQRNAYYSV  
LNTFQALHRSEAFRQLVHFVRDFAQ LKTSFRASSLAETTGPPKKRAKVDVATHGQTYGTL ELFQK M ILM  
HATYFLAAVLLGDHAEQVNTFLRLVFEIPLFSDTAVRHFRQRATVFLVPRRHGK TWFLVPLI ALASFR  
45 GIKIGYTAH RKA TE PV FDEI DA CLR GWF GSSR VDHVK GETISFSF PDGS RSTIVFA SHNTNG RGQDF

-13-

NLLFVDEANFIRPAVQTIMGFLNQANCKIIFVSSTNTGCASTSFLYNLRGAADELLNVVTVYICDDHMP  
 VVTHTNATACSCYILNKPVIFTMDGAVRRTADLFLPDSFMQEIIIGGQARETGDDRPVLTKSAGERFLLYR  
 PTTTNSGLMAPELYVYVDPAPFTANTRASGTGIAVVGRYRDDFIIFALEHFFLALTGSAPADIARCVVH  
 5 SLAQVLALHPGAFRSVRVAVEGNSSQDSAVAIATHVHTEMHRLASAGANGPGPELLFYHCEPPGAVLY  
 PFFLLNKQKTPAFEYFIKKFNSSGVMASQELVSVTQLQTDPVEYLSEQLNNLIEETVSPNTDVRMYSGKR  
 NGAADDLMAVIMAIYLAAPTGIPPAFFPITRTS  
 >gi\_59501  
 MFGQQLASDVQQYLERLEKQRQLKVGADAEASAGLTMGGDALRVPFLDFATATPKRHQTVVPGVGLHDC  
 EHSPLFSAVARRLLFNSLIVPAOLKGRDFGGDHTAKLEFLAELVRAVARLRFKECAPADVVPQRNAYYSV  
 10 LNTFQALHRSEAFRQLVHFVRDFAQLLKTSFRASSLTETTGPPKKRAKDVATHGRTYGTLELFQKMLM  
 HATYFLAAVLLGDHAEQVNTFLRLVFEIPLFSDAAVRHFRQRATVFLVPRRHGKTWFLVPLIALSLASFR  
 GIKIGYTAHIRKATEPVFEEIDACLRGWFGSARVDHVKGETISFSFPDGSRSTIVFASSHNTNGIRQDF  
 NLLFVDEANFIRPAVQTIMGFLNQANCKIIFVSSTNTGCASTSFLYNLRGAADELLNVVTVYICDDHMP  
 VVTHTNATACSCYILNKPVIFTMDGAVRRTADLFLADSFMQEIIIGGQARETGDDRPVLTKSAGERFLLYR  
 15 PTTTNSGLMAPDLYVYVDPAPFTANTRASGTGIAVVGRYRDDFIIFALEHFFLALTGSAPADIARCVVH  
 SLTQVLALHPGAFRGVRVAVEGNSSQDSAVAIATHVHTEMHRLASAGADAGSGPELLFYHCEPPGSAVL  
 YPFFLLNKQKTPAFEHFIKKFNSSGVMASQEIIVSATVRLQTDPVEYLLEQLNNLTETVSPNTDVRTYSGK  
 RNGASDDMLMAVIMAIYLAAQAGPPHTFAPITRV  
 >gi\_2605992  
 20 MFGKALSRETIQYFETLRKEVQSRSGAKNRAAEAQGGEDDVKTAFLNFAIPTPQRHQTVVPGVGLHDC  
 CETAQIFASVARRLLFRSLSKWRGGESKERLDPSSVEAYVDPKVKQALKTISFVEYNDEARSCRNAV  
 YSIMNTFDLSRSSDAFHQVANFVARFSRLVDTDSFNGADLDGQGQTSKRIKDVPTYGKQRGTLLELFQKML  
 MHATYFIAAVILGDHADRIGAFLKMVFNTPEFSDATIRHFRQRATVFLVPRRHGKTWFLVPLIALALATF  
 KGIKIGYTAHIRKATEPVFDEIGARLRLQWFGNSPVDHVKGGENISFSFPDGSKSTIVFASSHNTNGIRQD  
 25 FNLLFVDEANFIRPEAVQTIIIGFLNQTNCKIIFVSSTNTGCASTSFLYNLKGAADELLNVVTVYICDEHME  
 RVKAHTNATSCSCYILNKPVIFTMDGAMRNTAELFLPDSFMQEIIIGGGNISGAHRDEPVFTKTAQDRFLL  
 YRPSTVANQDIMSSNLYVYVDPAPFTTNAMASGTGIAVVGRYRSNWIVFGLEHFFLSALTGSSAELIARCV  
 AQCLAKVFAIHSPFDSVRIAVEGNSSQDAAVAIATNIQLELNTLQADVVHMPGTVLFYHCTPPGSSVA  
 YPFFLLQKQKGTGAFDHFIKAFNSGLVLAQELISNTVRLQTDPVEYLLTQMKNLTEVITGTSETRVFTGK  
 30 RNGASDDMLVALVMAVYMASLPPTTNAFSSLSTQ  
 >gi\_330792  
 MFGRVLGRETQYFPEALRREVQARRGAKNRAAEAQNGGEDDAKTAFLNFAIPTPQRHQTVVPGVGLHDC  
 CETAQIFASVARRLLFRSLSKWQSGEARERLDPSSVEAYVDPKVRQALKTISFVEYSDEARSCRNAV  
 YSIMNTFDLSRSSDAFHQVANFVARFSRLVDTDSFNGADLDGQGQASKARADVPTYGKQRGTLLELFQKML  
 35 MHATYFIAAVILGDHADRIGAFLKMVFNTPEFSDATIRHFRQRATVFLVPRRHGKTWFLVPLIALALATF  
 KGIKIGYTAHIRKATEPVFDEIGARLRLQWFGNSPVDHVKGGENISFSFPDGSKSTIVFASSHNTNGIRQD  
 FNLLFVDEANFIRPEAVQTIIIGFLNQTNCKIIFVSSTNTGCASTSFLYNLKGAADDLLNVVTVYICDEHME  
 RVKAHTNATACSCYILNKPVIFTMDGAMRNTAELFLPDSFMQEIIIGGGNISGAHRDEPVFTKTAQDRFLL  
 YRPSTVANQDIMSSNLYVYVDPAPFTTNAMASGTGIAVVGRYRSNWVFGMEHFFLSALTGSSAELIARCV  
 40 AQCLAKVFAIHSPFDSVRIAVEGNSSQDAAVAIATNIQLELNTLRRADVVPMGAVLFYHCTPHGSSVA  
 YPFFLLQKQKGTGAFDHFIKAFNSGSVLAQELVSNTVRLQTDPVEYLLTQMKNLTEVITGTSETRVFTGK  
 RNGASDDMLVALVMAVYMLSSLPPTSDFSSLPAQ  
 >gi\_971317  
 MFGGAVGEQSARYFQRLRERQRRAERGARPDGGGGARGEDDARVPFLDFAVAAPKRHQTVVPGVGLH  
 45 GYCELAPLFAATASRLLLTSMARAEAGLNTGTGEAHVSRELAVLSSALRFAAHPPAEAAHCNAYHSVMA  
 ALESMRASGAFQAQVAAFVARFSRLVGTSFSHLGGGDDADPPRAKRARVEPPSGQTRGALELFQKMLMPA

-14-

TYFVAATLLGEHAERIGAFLRVAFNTPDFSDAAVAHFRQRATVFLVPRRHGKTWFLVPLIALALATFKGI  
 KIGYTAHIRKATEPVFEEIVARLRQWFGERVDHKGEVISFSFPDGARSTIVFASSHNTNGIRGQDFNL  
 LFLVDEANFIRPEAVQTIVGFLNQASCKIIFVSSTNTGASTSFLYNLKGASDGLNNVVTVICNEHTPRVA  
 AHGGATAACSCYVLNKPVIFITMDAARNTAETFLPNFSMQUEIIGGGEVARRAEPAAVFTRAAGEQFLYR.P  
 5 STAAARGPWPRLYMYIDPAFTSNARASGSGIAVVGRRHGSWLVLGLEHFFLPALTGSSAAEIARCAVRC  
 FAQVMVAHRRRLDGLFVAVEGNSSQDSAVAIAGVRRELDLSAASGAVPMPAETRFYHCRPPGSAVAYPF  
 FLLQKQKTAAFDHFIRLFNSGRVVASQDLASLTVRLOQTDPEVEYLFEQLQNLTESTAGPGGARAFSGKRRG  
 AADDLMVALVMAVFVGSLLPTDGAFCPLAPRPPAD  
 >gi\_5869808  
 10 MSЛИMFGRTLGEESVRYFERLKRRDERFGTLESPTPCSTRQGSLGNATQIPFLNFAIDVTRRHQAVIPG  
 IGTЛHNCCEYIPLFSATARRAMFGAFLSSTGYNCTPNVVLKPWRYSVNANVSPELKKAVSSVQFYEYSP  
 EAAPHRNAYSGVMNTFRAFSLSDSFCOLSTFTQRFSYLVETSFESIEECGSHGKRAKVDVPIYGRYKGL  
 ELFQKMLMHTTHFISSVLLGDHADRVDCFLRTVFNTPSVSDSVLEHFKQKSTVFLVPRRHGKTWFLVPL  
 IALVMATFRGIKVGYTAHIRKATEPVFEGIKSRLEQWFGANVVDHVKGESITFSFTDGSYSTAVFASSHN  
 15 TNGIRGQDFNLLFVDEANFIRPDAVQTIVGFLNQTNCKIIFVSSTNTGASTSFLYNLRGSSDQLLNVVT  
 YVCDHMPRVLAHSVTACSCYVLNKPVFTIMDGAMRRTADLFMADSFVQEIVGGRKQNSGGVGFDRPLF  
 TKTARERFILYRPSTVANCAILSSVLYVYVDPAFTSNTRASGTGVAIVGRYKSDWIIFGLEHFFLRAITG  
 TSSSEIGRCVTQCLGHILALHPNTFTNVHVSIEGNSSQDSAVAIISIAIAQQFAVLEKGNVLSSAPVLLFY  
 HSIPPGCSVAYPFFLQKQKTPAVDVFVKRFNSGNIIIASQELVSLTVKLGDPVEYLCKQLDNLTEVIKG  
 20 GMGNLDTKTYTGKTTGMSDDLMVALIMSVYIGSSCIPDSVFMPIK  
 >gi\_5708110  
 MLGKESVEIVKRYRDALRKRTMERGPDDVDGQEMSDSNFITTASICDRNDSARDTMNSPASRFQFAIDVP  
 QRHOACIAPIGSFHNCCAIISRAFSYMASEIIYENLASYSTKYTDTDAALNDLQVSPKRQLFTGAAEDSIL  
 PALRQKLANLNFARFAPSDSLHDKAFDGIMNGYRGFVKSDEFSQLNNFIYRFHTLLKKSFGQASNDYK  
 25 RAKLEKTTSEQRDGTLELFQKMLMHTYFASSICLGEGSTERSNRYLSTVFNLSLFSENIIQHFRQRTT  
 VFLVPRRHGKTWFLVPLISLLVSSFEGIRIGYTAHLRKATEPVFIEIFTRLYKWFGAKQVEQVKGETITF  
 TFRNGNKSIAIVFASSQNTNLRQDFNFLFVDEANFIKAALHTVMGFLNQTNCKLFFVSSTNTCHSNTS  
 LLYNLKGKTNSSLNVVTVICDEHHMPETQKRTDVTCSCYVLHKPVFSMDSEVRNTADLFVKDSFMHEIA  
 GGRAGKYDSRTLVPVRALDQFLIYRPSTSSKPNISGLGKILTVYVDPAFFTNRSASGTGIALVTALRDS  
 30 MVLMGAEHFYLDALTGEAALEIAQCVYLCIAYCCLIAGAFREIRIARAVEGNSSQDSAAAIAGNLTELDS  
 ERRRLGFSLTFAHSRQPGTAMAHFVLLNKQKSRAFDLFVSLFNSGRFMASQELVSNLVLSKDPCCEYLV  
 DQIRNITVTHGQGPDSFRTFSGKQGRVPDDMLVAAMSTYLAEGSPTAGYHPIAPIGRRQRPA  
 >gi\_1813970  
 MLRGDSAAKIQERYAELQKRKSHPTSCISTAFTNVATLCKRYQMMHPELGLAHSNEAFLPLMAFCGRH  
 35 RDYNSPEESQRELLFHERLKSALDKLTFRPCSEEQRASYQKLDALTELYRDPQFQQINNFMTDFKKWL  
 GFSTAVEGDAKAIRLEPFQKNNLLIHVIFFIAVTKIPVLANRVLQYLIHAQFQIDFLSQTSIDIFKQKATVF  
 LVPRRHGKTWFLTPIISFLKHMIGISIGYVAHQHVSQFVLKEFRCRHTFARDYVVENKDMVISIDH  
 RGAKSTALFASCYNTNSIRGQNFHLLLVDDEAHFIKEAFNTILGFLAQNTTKIIFISSTNTSDSTCFLT  
 RLNNAPFDMLNVSYVCEEHLSFTEKGDATACPYCRLHKPTFISLNSQVRKTANMFMPGAFMDEIIGGT  
 40 NKISQNTVLLTDQSRREEFDILRYSTLNNTNAYDYFGKTLVYVLDPAFTTNRKASGTGVAAVGAYRHQFLIY  
 GLEHFFLRLDLSSESEVAIAECAAHMIIISVLSLHPYLDELRIAVEGNTNQAAAVRIACLIQSVQSSTLIR  
 VLFYHTPDQNHIEQPFYLMGRDKALAVEQFISRFNSGYIKASQELVSYTIKLSHDPIEYLLEQIQNLHRV  
 TLAEGTTARYSAKRQNRISDDLIIAVIMATYLCDDIHAIRFRVS  
 >gi\_2746296  
 45 MLRSCDIDAIQKAYQSIIWKHEQDVKISSTFPNSAIFCQKRFIIILTPELGFTHAYCRHVKPLYLFCDRQR  
 HVKSKIAICDPLNCALSKLKFTAIIEKNTEVQYQKHLELQTSFYRNPMFLQIEKFIQDFQRWICGDFENT

-15-

NKKERIKLEPFQKSILIIIFIISVTKLPTLANHVLDYLYKFDIEFINESSVNILKQKASVFLVPRRHG  
 KTWFMPVICFLLNLEGISIGYVAHQHVSHFVMKDVEFKCRRFPQKNITCQDNVITIEHETIKSTAL  
 FASCYNTHSIRGOSFNLLIVDESHFIKKDAFSTILGFLPQSSKIIIFISSTNSGNHSTSFLTKLSNSPFE  
 MLTVVSYVCEDHVHILNDRGNATTCACTYRHLKPKFISINADVKKTADLFLEGAFKHEIMGGSLCNVNDT  
 5 LITEQGLIEFDLFRYSTISKQIIPFLGKELYIYIDPAYTINRRASGTGAAIGTYGDQYIIYGMEHYFLE  
 SILSNSDASIAECASHMILAVLLELPFFTELKIIIEGNSNQSSAVKIACTILKQTISVIRYKHITFFHLD  
 QSQIAQPFYLLGREKRLAVEYFISNFNSGYIKASQELISFTIKITYDPIEYVIEQIKNLHQININEHVTVY  
 NAKKQTCSDLLIIIMAIYMCHEGKQTSFKEI  
 >gi\_325496  
 10 MLRTCDITHIKNNYEAIIWKGERCSTISTKYPNSAIFYKKRFIMLTPELGFAHSYNQQVKPLYTFCEKQ  
 RHLKRNKPPLTILPSLSHKLQEMKFLPASDKSFESQYTFLESFKILYREPLFLQIDGFIKDFRKWIKEF  
 NDFGDTRKIQLEPFQKNILIIHIVFFIAVTKLPALANRVINYLTHVFDIEFVNESTLNTLKQKTNVFLVPR  
 RHGKTFWTFIVPIISFLLNIEGISIGYVAHQHVSHFVMKEVFCKCRMFPEKTITCLDNVITIDHQNIKS  
 15 TALFASCYNTHSIRGOSFNLLIVDESHFIKKDAFSTILGFLPQASTKILFISSTNSGNHSTSFLMKLNN  
 SPFEMLSVVSYVCEDHAHMLNERGNATACSCYRLHCKPKFISINAEVKKTANLFLEGAFIHEIMGGATCNV  
 INDVLITEQGQTEFEFFFRYSTINKNLIPFLGKDLYVYLDPAYTGNRRASGTGAAIGTYLDQYIVYGMEH  
 YFLESILMTSSDTAIAECAAHMILSILDLHPFFTEVKIIIEGNSNQASAVKIACTIKENITANKSIQVTF  
 HTPDQNQIAQPFYLLGKEKKLAVEFFFISNFNSGNIKASQELISFTIKITYDPVEYALEQIRNIHQISVNN  
 YITYSAKKQACSDLLIIIAIMAIYVCSGNSSASFREI  
 20 >gi\_854039  
 MKLNNSPFEMLSVVSYVCEDHAHMLNERGNATACSCYRLHCKPKFISINAEVKKTANLFLEGAFIHEIMGG  
 ATCNVINDVLITEQGQTEFEFFFRYSTINKNLIPFLGKDLYVYLDPAYTGNRRASGTGAAIGTYLDQYIV  
 YGMEHYFLESILMTSSDTAIAECAAHMILSILDLHPFFTEVKIIIEGNSNQASAVKIACTIKENITANKSI  
 QVTFHHTPDQNQIAQPFYLLGKEKKLAVEFFFISNFNSGNIKASQELISFTIKITYDPVEYALEQIRNIHQ  
 25 ISVNNYITYSAKKQACSDLLIIIAIMAIYVCSGNSSASFREI  
 >gi\_5733564  
 MLRTCDITHIKNNYEAIIWKGERCSTISTKYPNSAIFYKKRFIMLTPELGFAHSYNQQVKPLYTFCEKQ  
 RHLKRNKPPLTILPSLTRKLQEMKFLPASDKSFESQYTFLESFKILYREPLFLQIDGFIKDFRKWIKEF  
 NDFGDTRKIQLEPFQKNILIIHIVFFIAVTKLPALANRVINYLTHVFDIEFVNESTLNTLKQKTNVFLVPR  
 RHGKTFWTFIVPIISFLLNIEGISIGYVAHQHVSHFVMKEVFCKCRMFPEKTITCLDNVITIDHQNIKS  
 30 TALFASCYNTHSIRGOSFNLLIVDESHFIKKDAFSTILGFLPQASTKILFISSTNSGNHSTSFLMKLNN  
 SPFEMLSVVSYVCEDHAHMLNERGNATACSCYRLHCKPKFISINAEVKKTANLFLEGAFIHEIMGGATCNV  
 INDVLITEQGQTEFEFFFRYSTINKNLIPFLGKDLYVYLDPAYTGNRRASGTGAAIGTYLDQYIVYGMEH  
 FLESILMTSSDTAIAECAAHMILSILDLHPFFTEVKIIIEGNSNQASAVKIACTIKENITANKSIQVTF  
 35 TPDQNQIAQPFYLLGKEKKLAVEFFFISNFNSGNIKASQELISFTIKITYDPVEYALEQIRNIHQISVNN  
 ITYSAKKQACSDLLIIIAIMAIYVCSGNSSASFREI  
 >gi\_4996048  
 MKLNNSPFEMLSVVSYVCEDHAHMLNERGNATACSCYRLHCKPKFISINAEVKKTANLFLEGAFIHEIMGG  
 ATCNVINDVLITEQGQTEFEFFFRYSTINKNLIPFLGKDLYVYLDPAYTGNRRASGTGAAIGTYLDQYIV  
 40 YGMEHYFLESILMTSSDTAIAECAAHMILSILDLHPFFTEVKIIIEGNSNQASAVKIACTIKENITANKSI  
 QVTFHHTPDQNQIAQPFYLLGKEKKLAVEFFFISNFNSGNIKASQELISFTIKITYDPVEYALEQIRNIHQ  
 ISVNNYITYSAKKQACSDLLIIIAIMAIYVCSGNSSASFREI  
 >gi\_1136808  
 MLLSRHRERLAANLEETAKDAGERWELSAPTFTRHCPKTARMAHPFIGVWHRINSYSSVLETYCTRHHPA  
 45 TPTSANPDVGTPRPSEDNVPAKPRILLESLSTYLMQRCVREDAHVSTADQLVEYQAGRKTHDSLHACSVYR  
 ELQAFLVNLSSFLNGCYVPGVHWLEPFQQQLVMHTFFFLLVSIKAPQKTHQLFGLFKQYFGLFETPNSVLO

-16-

TFKQKASVFLIPRRHGKTWIVVAAISMILLASVENINIGYVAHQKHVANSVFAEIIKTLCRWFPPKNLNIK  
 KENGTTIYTRPGGRSSSLMCATCFNKNISRQGTFNLLYVDEANFIKKDALPAILGFMLQKDAKLIFISSV  
 NSSDRSTSFLNLRNAQEKMNVVSVCADHREDFHLQDALVSCPCYRLHIPTYITIDESIKTTTNLFME  
 GAFDTELMGEGAASSNATLYRVVGDAAALTQFDMCRVDTTAQEVQKCLGKQLFVYIDPAYTNNTAESGTGV  
 5 GAVVTSTQTPTRSLSLILGMEMHFLRDLITGAAAYEIASCACTMIKAIAVLHPTIERVNAAVEGNSSQDSGV  
 IATVLNEICPLPIHFLHYTDKSSALQWPIYMLGGEKSSAFETFIYALNSGTLASQTVVSNTIKISFDPV  
 TYLVEQVRAIKCVPLRDGGQSYSAKQKHMSSDILLVAVVMAHFMATDDRHMYKPISP  
 >gi\_1718281  
 MLQKDAKLIFISSVNSSDRSTSFLNLRNAQEKMNVVSVCADHREDFHLQDALVSCPCYRLHIPTYIT  
 10 IDESIKTTTNLFMEGAFDTELMGEGAASSNATLYRVVGDAAALTQFDMCRVDTTAQEVQKCLGKQLFVYID  
 PAYTNNTAESGTGVGAVVTSTQTPTRSLSLILGMEMHFLRDLITGAAAYEIASCACTMIKAIAVLHPTIERVN  
 AAVEGNSSQDSGVIAITVLNEICPLPIHFLHYTDKSSALQWPIYMLGGEKSSAFETFIYALNSGTLASQ  
 20 TVVSNTIKISFDPVTYLVEQVRAIKCVPLRDGGQSYSAKQKHMSSDILLVAVVMAHFMATDDRHMYKPISP  
 Q  
 >gi\_2246515  
 MLQKDAKLIFISSVNSSDRSTSFLNLRNAQEKMNVVSVCADHREDFHLQDALVSCPCYRLHIPTYIT  
 IDESIKTTTNLFMEGAFDTELMGEGAASSNATLYRVVGDAAALTQFDMCRVDTTAQEVQKCLGKQLFVYID  
 PAYTNNTAESGTGVGAVVTSTQTPTRSLSLILGMEMHFLRDLITGAAAYEIASCACTMIKAIAVLHPTIERVN  
 AAVEGNSSQDSGVIAITVLNEICPLPIHFLHYTDKSSALQWPIYMLGGEKSSAFETFIYALNSGTLASQ  
 25 TVVSNTIKISFDPVTYLVEQVRAIKCVPLRDGGQSYSAKQKHMSSDILLVAVVMAHFMATDDRHMYKPISP  
 Q  
 >gi\_2246552  
 MLLSRHRERLAANLQETAKDAGERWELSAPTFTRHCPKTARMAHPFIGVVRINSYSSVLETYCTRHHPA  
 TPTSANPDVGTPRPSEDNVPAKPRLLSLSLSTYLOMRCVREDAHVSTADQLVEYQAARKTHDSLHACSVYR  
 30 ELQAFLVNLSSFLNGCYVPGVHWLEPFQQQLVMHTFFFLLVSIAPKQKTHQFLGFLKQYFGLFETPNSVLLQ  
 TFKQKASVFLIPRRHGKTWIVVAAISMILLASVENINIGYVAHQKHVANSVFAEIIKTLCRWFPPKNLNIK  
 KENGTTIYTRPGGRSSSLMCATCFNKNISRQGTFNLLYVDEANFIKKDALPAILGFMLQKDAKLIFISSV  
 NSSDRSTSFLNLRNAQEKMNVVSVCADHREDFHLQDALVSCPCYRLHIPTYITIDESIKTTTNLFME  
 GAFDTELMGEGAASSNATLYRVVGDAAALTQFDMCRVDTTAQEVQKCLGKQLFVYIDPAYTNNTAESGTGV  
 35 GAVVTSTQTPTRSLSLILGMEMHFLRDLITGAAAYEIASCACTMIKAIAVLHPTIERVNAAVEGNSSQDSGV  
 IATVLNEICPLPIHFLHYTDKSSALQWPIYMLGGEKSSAFETFIYALNSGTLASQTVVSNTIKISFDPV  
 TYLVEQVRAIKCVPLRDGGQSYSAKQKHMSSDILLVAVVMAHFMATDDRHMYKPISP  
 >gi\_4494933  
 MLQKDAKLIFISSSSNNSDKSTSFLNLRDAHEKMLNVVNYVCPDHKDDFNLDQDTVVACPCYRLHIPAYIT  
 IDETVRSTTNLFLEGAFSTELMGDAATSAQSMHKIVSDSSLSQLDLCRVKSTSQDIQGAMKPCCLHVVYIDP  
 AYTNNTDASGTGIGAVIAVNHKVIKCCILLGVEHFFLRLDTGTAAYQIASCAAALIRAIVTLHPQITHVNV  
 AVEGNSSQDAGVIAITVLNEICSVPLSFLHHDKNTLIRSPIYMLGPEKAKAFESFIYALNSGTFASQTV  
 VVSHTIKLSFDPVAYLIDQIKAIRCIPLKDGGHTYCAKQKTMSSDDVLVAAVMAHYMATNDKFVFKSLE  
 >gi\_7330018  
 40 MLQKDAKLIFISSSSNNSDKSTSFLNLRDAHEKMLNVVNYVCPDHKDDFNLDQDTVVACPCYRLHIPAYIT  
 IDETVRSTTNLFLEGAFSTELMGDAATSAQSMHKIVSDSSLSQLDLCRVKSTSQDIQGAMKPCCLHVVYIDP  
 AYTNNTDASGTGIGAVIAVNHKVIKCCILLGVEHFFLRLDTGTAAYQIASCAAALIRAIVTLHPQITHVNV  
 AVEGNSSQDAGVIAITVLNEICSVPLSFLHHDKNTLIRSPIYMLGPEKAKAFESFIYALNSGTFASQTV  
 VVSHTIKLSFDPVAYLIDQIKAIRCIPLKDGGHTYCAKQKTMSSDDVLVAAVMAHYMATNDKFVFKSLE  
 45 >gi\_4019255  
 MLLKAKKALMENLTEASSTQSETEWTVDPTMITNIKKSERMAYSKIGVIPSINLYSASLTSFCRLYRP

-17-

LALKQPLPQTGTLRLLPSEKPYISQKLSNYVKSLLKHWHDIEAEAEYYASVQTEKTFMECPIYLELRO  
 FIINLSSFLNGCYVKKSTHIEPFQQLQILHFTYFLISIKSPESTNKLFDIFKEYFGLGEMDSAMLNQFKQ  
 KASIFLIPRRHGKWTIVVAAISMLITSVENLHVGYVAHQKHVANSVFTEIINTLQKWFPSKNIDVKKEENG  
 5 TIIYKIPGKKPSTLMCAFNKNSIRGQTFNLLYIDEANFIKKDSLPAILGFMLQKDAKLIFISSVNSGD  
 KATSFLFNLKNASEKMLNIVNYICPDHKDDFLQDSLISCPYKLYIPTYITIDETIKNTTNLFLDGAFT  
 TELMGDISVMSKNNIHKVIGETALMQFDLRCIDTTKPEITQCLNSIMLYIDPAYTNNSEASGTGIGAI  
 ALKNNSSKCIIVGIEHYFLKDLTGTATYQIASCACSLIRAALVLYPHIQAVHVAVEGNSSQDSAISTF  
 LNECSPVKVNFMHYKDKTAMQWPIYMLGSEKSQAFESFIYAI NSGTISASQSIISNTIKLTFDPISYLI  
 EQIRAIRCYPLRDGSHTYCAKRTVSDDVLVAVVMAFFSTSINKHIFKQLNSI  
 10 >gi\_4019257  
 MLQKDAKLIFISSVNSGDKATSFLFNLKNASEKMLNIVNYICPDHKDDFLQDSLISCPYKLYIPTYIT  
 IDETIKNTTNLFLDGAFTTELMGDISVMSKNNIHKVIGETALMQFDLRCIDTTKPEITQCLNSIMLYID  
 PAYTNNSEASGTGIGAI IALKNNSSKCIIVGIEHYFLKDLTGTATYQIASCACSLIRAALVLYPHIQAVH  
 15 VAVEGNSSQDSAISTFLNECSPVKVNFMHYKDKTAMQWPIYMLGSEKSQAFESFIYAI NSGTISASQ  
 SIISNTIKLTFDPISYLI EQIRAIRCYPLRDGSHTYCAKRTVSDDVLVAVVMAFFSTSINKHIFKQLNS  
 I  
 >gi\_60355  
 MLLKAKKAIENLSEVSSTQAETDWDMSPTIITNTSKSERTAYSKIGVIPSVNLYSSTLTSFCKLYHP  
 LTLNQTQPQTGTLRLLPHEKPLILQDLSNYVLLTSQNVCNDTEANTEYNAAVTQKTSMECPITLELRO  
 20 FVINLSSFLNGCYVKRSTHIEPFQQLQILHFTYFLISIKSPESTNRLFDIFKEYFGLREMDPMLQIFKQ  
 KASIFLIPRRHGKWTIVVAAISMLITSVENLHVGYVAHQKHVANSVFTEIINTLQKWFPSRYIDIKKENG  
 TIIYKSPDKKPSTLMCAFNKNSIRGQTFNLLYIDEANFIKKDSLPAILGFMLQKDAKLIFISSVNSGD  
 RATSLFLFNLKNASEKMLNIVNYICPDHKDDFLQDSLISCPYKLYIPTYITIDETIKNTTNLFLDGAFT  
 TELMGDMMSGISKSNMHKVISEMAITQFDLRCADTTKPEITQCLNSTMYIYIDPAYTNNSEASGTGIGAIL  
 25 TFKNNSSSKCIIVGMEHYFLKDLTGTATYQIASCACSLIRASLVLPHIQCVHVAVEGNSSQDSAISTL  
 INECSPIKVYFIHYKDKTAMQWPIYMLGAEKSIAFESFIYAI NSGTISASQSIISNTIKLSFDPISYLI  
 EQIRSIRCYPLRDGSHTYCAKRTVSDDVLVAVVMAYFFATSINKHIFKPLNST  
 >gi\_695201  
 MLQKDAKIIIFISSVNSSDQTTFLYNLKNAKEKMLNVNVYCPQHREDFSLQESVVSCPCYRLHIPTYIA  
 30 IDENIKDTTNLFMEGAFTELMGDGAAATTQTNMHKVVGEPALVQFDLRCVDTGSPEAQRGLNPTLFLYV  
 DPAYTNNTEASGTGMAVVSMNSDRCVVVGVEHFFLKELTGASSLQIASCAAIRSLATLHPFVREAH  
 VAIEGNSSQDSAIAVATLLHERSPLPVKFLHHADKATGVQWPMLGAEKARAFETFIYALNSNTLSCGQ  
 AIVSNTIKLSFDPVAYLIEQIRAIRCYPLKDGTVSYCAHKGGSDDTLVAVVMAHYFATSDRHVFKNHMK  
 QI  
 35 >gi\_4928934  
 MLLSSFRNHLQKNYEKYSVQAQNIDWPVETPVLISKDSKTNRLAHPLIGVISRINLYSPTLKYYCDEYST  
 TKQPKFTPDIGYVRLKKHDQYFLPKLQHLLSTLCEAYNHVDRQAQVEFNASILTLKAFNANGVNLNELKQ  
 FLINLSCFLNGCYVSKSTCIELFKQQLILHFTYFLISIKTPEETNKMFHVKHYVGLFDIDDNMLQCFKQ  
 KSTVFLIPRRHGKWTIVVAAISVILLASVENHVIGYVAHQKHVANAVFTEIITTLQWFPSSKNEIJKKENG  
 40 TIIYTKPGRKPSLCAFNKNSIRGQTFNLLYVDEANFIKKALPA ILGFMLQKDAKIIIFISSVNSAD  
 KSTSFLFNLRNAKEKMLNVNVYCPHEKDFNLQSTLSCPCYRLHIPTYITIDESIKNTTNLFLDDVFT  
 TELMGDISTFPTSSMFVVEEQLFHFIDCRVDTTQIDTVKIIDNVLYVYVDPAYTSNSEASGTGIGAVV  
 PLKTKVKTIIIGIEHFYLNLTGTASQQIAYCVTSMIKAILTLHPHINHVNVAVEGNSSQDSAISTF  
 NEYCPVPVFFAHNCNERSSVFQWPIYILGSEKSQAFEFKICALNTGTLASQQTIVSNTIKISFDPVAYLME  
 45 QIRAIRCLPLKDGSYTYCAKQKTMSSDTLVAVVMANYMAISEKHTFKELCKT  
 >gi\_1632798

-18-

MLYASQRGRLTENLRNALQQDSTTQGCLGAETPSIMYTGAKSDRWAHPLVGTIHASNLYCPMLRAYCRHY  
 GPRPVFVASDESLPMFGASPALHTPVQVQMCLLPELRTLQRLLPPNLEDSEALTEFKTSVSSARAIL  
 DPNFLEMREFVTSLASFQKQYKHPARLEAFQKQVVLHSFYFLISIKSLEITDTMFIFQSAFGLLEMT  
 LEKLHIFKQKASVFLIPRHRGKTIWVVAIISLILSNSLNSVQIGYVAHQHVAVAVFTEIIDTLTKSFDSK  
 5 RVEVNKETSTITFRHSGKISSTVMCATCFNKSIRGQTFHLLFVDEANFIKKEALPAILGFMLQKDAKII  
 FISSVNSADQATSFLYKLKDAQERLLNVVSYVCQEHROQDFMDQDSMVSCPCFRHLIPSYITMDSNIRATT  
 NLFLDGAFSTELMGDTSSLSQGSLSRVRRDAINQLELCRVDTLNPRVAGRASSLYVYVDPAYTNNTSA  
 SGTGIAAVTHDRADPNRVIVLGLEYHFFLKDQALQIATCVVALVSSIVTLHPLHEEVKVAEGNNSQ  
 DSAVIAIASIIGESCPLPCAFAVHTKDKTSSLQWPMLLTNEKSKAFLYIAYVNTASLSASQVTVSNTIQL  
 10 SFDPVLYLISQIRAIKPIPLRDGTYTYTGKQRLNSDDVLVALVMAHFLATTQKHTFKKVKH  
 >gi\_2337991  
 MFYVKVMPALQKACEELQNQWSAKSGKWPVPETPLVAVETRRSERWPHYIQLLPGVAAYSSTLEDYCHL  
 YNPYIDALTRCDLGQTHRRVATQPVLSDQLCQQLKQLFSCPRNTSVKAKLEFEAAVRTHQALDNSQVFLE  
 LKTFVLNLSAFLNLRKYSDRSSHIELFQKQLIMHTFFFIVSIIKAPELCEKFCNIFKLYFNIDTMDQATLDI  
 15 FKQKASVFLIPRHRGKTIWVVAIISILLASVQDLRIGYVAHQHVAVAVFTEVINTLHTFFPGKYMDVKK  
 ENGTIIFGLPNKPKPSTLLCATCFNKSIRGQTFQLLFVDEANFIKKDALPTILGFMLQKDAKIIIFISSSN  
 SSDQSTSFLYNLKGASERMLNVVSYCSNHKEFDSMQDGLISCPCSYLHVPSYISIDEQIKTTNLFLDG  
 VFDTELMGDSCTLSTFQIISESALSQFELCRIDTASPVQAHLNSTVHMYIDPAFTNNLDASGTGISV  
 20 IGRIGAKTKVILGCEHFFLQKLTGTAALQIASCATSLRSVIIHPMIKCAQITIEGNSSQDSAVAIANF  
 IDECAPIPVTFYHQSDKTKGVLCPLYLLGQEKAVAFESFIYAMNLGLCKASQLIVSHTIKLSFDPVYLL  
 EQVRAIKCQSLRDGSHTYHAKQKNLSSDDLLVSVVMSLYLSSANTLPFKPLHIERF  
 >gi\_2317977  
 MLQKDAKIFFISSVNSGEKTTFLYNLKDAKEVNVSYVCSEHMEDFNQSAITACPCYRLVPEFIT  
 INDNIKCTTNLLLEGSFATELMGNMQSHTEVGNSMIHESSLTRLDFYRCDTAGQGAPTTENTLFVYIDP  
 25 AYGNVNVHASGTGIVAMSHCKHTKKCIIILGLEHFFLNNLTGTAHHNIASCATLLEGILFQHPWIQEIRCI  
 IEGNSNQDSAVAIATFISHNIKLPTLFASYRDKTGMQWPIYMLSGDKTLAFQNFISSLNQGILLCASQTV  
 SNTVLLSSDPISYLLIEQIKNTKCIYHKNKTITFQSKTHTMSDDVLIACVMTCYVMTTNKISYISFSIK  
 >gi\_6625593  
 MFIASKSYFEAVYRSTVSSHSEEFWKSDDPVYFTQYKKQCNRLPNAYLGLTHSASKYSENFRHYVATFS  
 30 NSPLDFPQSVFNERNPCEYSPYLDALQCSAKTLVGCSVSTTERNEYEVCKEATRCFKDAMSHKVLKVF  
 LSNLSWFLKGHKSKQAFLEPFQKQLLHSFMVASIKCPETTTKLFDFKFLLDMLYFDNTDLLTFLQK  
 SPAFLIPRHRGKTIWVTAIISMLLTSVDDLHIGYVAHQHVSLAVFILEISNTLLAWFPRKNIDIKKENGV  
 ILYSHPGKKSSTLMCATCFNKSIRGQTFNLLFVDEANFIKKEALPAILGFMLQKDAKIFFISSVNSGEK  
 TTSFLYNLKDANEKVNVSYVCSEHMEDFNQSAITACPCYRLVPEFITINDNIKCTTNLLLEGSFAT  
 35 ELMGNMQSHTEVGNSMIHESSLTRLDFYRCDTAGQGAPTTENTLFVYIDPAYGNNVHASGTGIVAMSHC  
 KHTKKCIIILGLEHFFLNNLTGTAHHNIASCATLLEGILFQHPWIQEIRCIIEGNSNQDSAVAIATFISH  
 NIKLPTLFASYRDKTGMQWPIYMLSGDKTLAFQNFISSLNQGILLCASQTVVSNTVLLSSDPISYLLIEQIK  
 NTKCIYHKNKTITFQSKTHTMSDDVLIACVMTCYVMTTNKISYISFSIK

TABLE 2

TABLE 2 CONTINUED

TABLE 2 CONTINUED

**SUBSTITUTE SHEET (RULE 26)**

TABLE 2 CONTINUED

**SUBSTITUTE SHEET (RULE 26)**

TABLE 2 CONTINUED

781	791
gi_10100719	
gi_7673189	YEATCRPTEA
gi_5689285	TS
gi_1869837	YS
gi_59501	
gi_2605982	q
gi_330792	q
gi_971317	RPPAD
gi_5863908	
gi_5708110	IGRRQPH
gi_1813970	
gi_2746296	
gi_325496	
gi_5733564	
gi_11336808	
gi_2246552	
gi_4019255	
gi_60355	
gi_4928934	FF
gi_2337991	
gi_1632298	
gi_6625593	
gi_1718281	
gi_2246515	
gi_4494933	
gi_7330018	
gi_4019257	
gi_695201	
gi_2317977	
gi_854039	
gi_4996048	
Consensus	..

TABLE 2 CONTINUED

-26-

Table 3. Degenerate primers generated by CODEHOP

## Block x7263xbliD

T L Y V Y I D P  
 oligo: 5'-AACCTGTACGTGtayntngaycc-3' degen=64 temp=33.4 Extend clamp

T L Y V Y I D P A  
 oligo: 5'-AACCTGTACGTGtACntngayccngc-3' degen=128 temp=36.0 Extend clamp

T L Y V Y I D P A Y  
 oligo: 5'-AACCTGTACGTGtACATngayccngcnt-3' degen=128 temp=42.5 Extend clamp

## Complement of Block x7263xbliD

Y I D P A Y T N N T  
 atrnanctrggGCGGATGTGGTTGTTGT  
 degen=64 temp=62.9

oligo: 5'-TGTTGTTGGTGTAGGCGGgrrtchanrta-3'

D P A Y T N N T R A  
 anctrggncgnaTGTGGTTGTTGTGGGTCCG  
 degen=128 temp=61.8

oligo: 5'-GCCTGGGTGTTGTTGGTGTangcnggrrtcna-3'

D P A Y T N N T R A  
 ctrggncgnaGTGGTTGTTGTGGGTCCG  
 degen=64 temp=61.0

oligo: 5'-GCCTGGGTGTTGTTGGTGWangcnggrrtc-3'

## Block x7263xbliE

C I I F G M E H F F  
 oligo: 5'-TGGATCATCTTCGGCATngarcaytwyt-3' degen=64 temp=55.7 Extend clamp

I F G M E H F F L  
 oligo: 5'-CATCTTCGGCATGGAGcaytwytwytt-3' degen=64 temp=62.0

## Complement of Block x7263xbliE

E H F F L R D L T G  
 ctygtrawrawGGACTTCCTGGACTGCC  
 degen=32 temp=61.7

oligo: 5'-CCCGTCAGGTCCCTTCAGGwarwartgytc-3'

H F F L R D L T G  
 tygtrawrawrrACTTCCTGGACTGCC  
 degen=128 temp=60.8

oligo: 5'-GCCCGTCAGGTCCCTTCArrwarwartgyt-3'

H F F L R D L T G  
 gtrawrawrraCTTCCTGGACTGCC  
 degen=64 temp=60.8

oligo: 5'-GCCCGTCAGGTCCCTTCarrwarwartg-3' degen=64

## Block x7263xbliF

E V H I A V E G N  
 oligo: 5'-GGACGTGCACTCGCCrtnargnnaa-3' degen=64 temp=63.8

## Complement of Block x7263xbliF

E G N S S Q D S A  
 anctycnnttrwGGTTGGTCCTGAGGCC  
 degen=128 temp=62.7

oligo: 5'-GGCGGAGTCCTGGTTGGwrttnccaytcna-3'

E G N S S Q D S A V  
 ctyccnnttrwsGTTGGTCCTGAGGCC  
 degen=64 temp=63.9

oligo: 5'-CGGCGGAGTCCTGGTTGswrttnccytc-3'

CLAIMS

1. A method of designing a panel of degenerate primer pairs for screening for new members of multiple known virus families in a biological sample, wherein each primer pair in the panel binds a sequence that is conserved across members of a said 5 virus family and selectively directs amplification of sequence of said family by PCR, which method comprises

(a) providing a plurality of amino acid sequences from members of a first virus family,

10

(b) comparing the sequences to identify conserved regions,

(c) designing a first primer pair using a computer based method, wherein each primer in the pair binds a nucleotide sequence that encodes a conserved region identified in

15 (b) and wherein the primer pair is designed to amplify by PCR the nucleotide sequence between the nucleotide sequences that encode conserved regions in members of the first virus family, and

(d) repeating steps (a) to (c) for each virus family.

20

2. A method of designing a panel of degenerate primer pairs for screening for new members of multiple known virus families in a biological sample, wherein each primer pair in the panel binds a sequence that is conserved across members of a said virus family and selectively directs amplification of sequence of said family by PCR,

25 which method comprises

(a) providing a plurality of nucleotide sequences from members of a first virus family,

30 (b) comparing the sequences to identify conserved regions,

-28-

(c) designing a first primer pair using a computer based method, wherein each primer in the pair binds a conserved region identified in (b) and wherein the primer pair is designed to amplify by PCR the nucleotide sequence between the conserved regions in members of the first virus family, and

5

(d) repeating steps (a) to (c) for each virus family.

3. A method according to claim 1 or 2 which further comprises synthesising one or more of the primer pairs and determining optimal conditions for using the primer 10 pairs in PCR.

4. A method according to any one of the preceding claims which comprises testing the ability of one or more of the primer pairs to amplify a nucleotide sequence that encodes an amino acid as defined in claim 1(a) or a nucleotide sequence as defined in 15 claim 2(a).

5. A method according to claim 3 or 4 which comprises testing the primer pair(s) in a range of buffer conditions to determine the optimal buffer conditions for PCR.

20 6. A method according to any one of claims 3 to 5 which comprises testing the primer pair(s) at a range of different temperatures to determine the optimal temperature for PCR.

7. A method according to any one of the preceding claims which comprises 25 identifying one or more groups of primer pairs wherein the primer pairs in each group have similar optimal conditions of use in PCR such that they can be used optimally in the same reaction vessel.

8. A method according to claim 7 wherein each primer pair in a group generates a 30 PCR product of a different size to the other primer pair(s) in the group.

-29-

9. A method according to claim 7 or 8 wherein each primer pair in a group carries a different label from the other primer pair(s) in the group.
10. A method according to claim 9 wherein each primer pair in a group carries a 5 differently-coloured fluorescent label.
11. A method according to any one of the preceding claims wherein the biological sample is a single-source sample from a single individual or is a pooled sample from more than one individual of the same species.
- 10
12. A method according to claim 11 wherein the biological sample is a human sample.
13. A method according to any one of the preceding claims wherein at least 50% of 15 the primer pairs bind a sequence that is conserved across all of the genera and/or subfamilies.
14. A panel of primers designed according to any one of the preceding claims.

**FIG 1****1/1**